Skip to main content

Table 1 Patient characteristics

From: Inhibition of effector B cells by ibrutinib in systemic sclerosis

SSc (n = 24)
Demographics
Age (years)
  Median54
  Range30–81
Sex
  Female15 (63%)
  Male9 (38%)
Disease characteristics
SSc subtype
  Limited cutaneous SSc14 (58%)
  Diffuse cutaneous SSc10 (42%)
Disease duration (years)
  Median8
  Range1.2–24
Modified Rodnan skin score
  Median8
  Range0–44
Autoantibodies
  Antinuclear antibodies (ANA)20 (83%)
  Anti-Scl-70 antibodies12 (50%)
  Anticentromer antibodies (ACA)6 (25%)
Pretreatment 
  Cyclophosphamide4 (17%)
  Mycophenolate mofetil2 (8%)
  Stem cell transplant (> 10 years before blood draw)2 (8%)
Immunosuppressive therapy at time of blood draw
  None18 (75%)
  Prednisolone2 (8%)
  Mycophenolate mofetil2 (8%)
  Methotrexate3 (13%)